clinical trial · NCT07030101
A Study to Investigate Efficacy and Safety of a TCA108 in Participants ≥18 Years With Uncontrolled Hypertension
EMS·phase3·not yet recruiting·n = 400
HypertensionTCA108Bramicar HCTMicardis Anlo
brief summary
The purpose of this study if to evaluate the efficacy and safety of TCA108 in the treatment of hypertension.
started
Nov 1, 2026
primary completion
May 1, 2029
completion
Nov 1, 2029
last updated
Nov 24, 2025
official title
A Phase 3 Double-blind, Multicenter, Randomized, Double-blind, Triple-dummy, Controlled Trial to Assess the Efficacy and Safety of a TCA108 in Participants ≥18 Years of Age With Uncontrolled Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol